Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis (NASDAQ: ACB) reported Q2 fiscal 2026 results for the quarter ended September 30, 2025, with consolidated net revenue of $90.4M (up 11% YoY) and global medical cannabis revenue of $70.5M (up 15% YoY).
Adjusted EBITDA rose 52% to $15.4M, adjusted net income was $7.1M, and adjusted gross margin before fair value adjustments improved to 61%. The company held $141.9M cash and reports a debt-free cannabis business (non-recourse Bevo debt separate).
Aurora Cannabis (NASDAQ: ACB) scheduled a conference call to discuss its second quarter 2026 results on Wednesday, November 5, 2025. The Company will release Q2 2026 financial results before market open that same day.
The live conference call is set for 8:00 a.m. Eastern Time / 6:00 a.m. Mountain Time. Miguel Martin, Executive Chairman and CEO, and Simona King, CFO, will host the call and the Q&A session. A live webcast link has been posted on the Company’s Investor Info page at https://www.auroramj.com/investors/ under Events.
Aurora Cannabis (NASDAQ:ACB) has announced a multi-year investment plan to upgrade its EU-GMP manufacturing facility in Leuna, Germany. The five-year operational enhancement project aims to increase flower growth capacity and improve product quality at one of only three licensed cultivation facilities in Germany.
The upgrades include adding new grow rooms, implementing improved irrigation and lighting systems, and transitioning to hang dry and dry trim processes. The facility, which currently produces IndiMed brand cultivars, will expand its product line using Aurora's genetics library. These improvements align with Aurora's strategy to strengthen its European presence and meet growing medical cannabis demand in the region.
Aurora Cannabis (NASDAQ: ACB) has launched the English version of the Physician Experience Platform (PEP) in partnership with German healthcare technology company Copeia. The platform serves as a peer-to-peer educational resource containing over 130 anonymized medical cannabis case studies for healthcare professionals.
Initially available to physicians in Canada, UK, Poland, Malta, Czech Republic, Australia, and New Zealand, PEP provides detailed clinical insights including patient history, symptoms, therapeutic outcomes, dosage data, and product recommendations. The platform, which follows the successful German version launch in 2024, requires DocCheck verification to ensure exclusive access for healthcare professionals.
Aurora Cannabis (NASDAQ: ACB), a leading global medical cannabis company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York City. CFO Simona King will conduct one-on-one investor meetings from September 8-10, 2025.
The presentation will focus on Aurora's strategic investments and plans for delivering long-term shareholder value in the medical cannabis industry. Investors can access the presentation via webcast through Aurora's investor relations website, with replay available for 90 days.
Aurora Cannabis (NASDAQ:ACB) has announced the launch of its premium brand Whistler Cannabis Co. in Australia, marking a significant expansion of its global medical cannabis footprint. The company will introduce two high-potency cultivars: Ginger Breath (32% THC) and Critical Diesel (28% THC), both available in 10g formats.
Whistler Cannabis Co., established in 2013, produces premium craft cannabis at Aurora's state-of-the-art Aurora Alpine facility in Pemberton Valley, British Columbia. The brand is known for its small-batch production, proprietary genetics, and meticulous hand-trimming process that preserves trichomes containing essential cannabinoids and compounds.
Aurora Cannabis (NASDAQ: ACB) held its 2025 Annual General and Special Meeting with 31.53% shareholder participation, representing 17.7 million shares. Five of six director nominees were successfully elected to the board, while Theresa Firestone resigned following a failed re-election bid with only 42.4% votes in favor.
The company announced key leadership changes, with Michael Singer appointed as new Lead Independent Director and Chair of the Human Resources and Compensation Committee. Shareholders approved Ernst & Young LLP as auditors and amendments to the company's RSU, PSU, and Share Option Plans. Notably, the "say-on-pay" advisory vote on executive compensation failed to receive majority support.
Aurora Cannabis (NASDAQ: ACB), Canada's largest medical cannabis company, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston, MA. CFO Simona King will engage in a fireside chat on August 13th at 1:30pm EST and hold one-on-one investor meetings.
The presentation will focus on Aurora's strategic direction, recent achievements, and growth prospects in the global medical cannabis market. Investors can access the live webcast through Aurora's investor relations website, with replay available for 90 days.
Aurora Cannabis (NASDAQ:ACB) reported strong Q1 2026 results, with total net revenue reaching $98.0 million, up 17% year-over-year. The company's global medical cannabis segment showed impressive growth, with revenue increasing 37% to $64.8 million, driven by an 85% surge in international markets.
Key financial highlights include Adjusted EBITDA of $10.8 million (up 209% YoY), positive free cash flow of $9.2 million (up 42%), and adjusted gross margin of 52%. The company maintains a strong balance sheet with $186.0 million in cash and a debt-free cannabis business.
International medical cannabis now represents 57% of global medical cannabis revenue, with significant growth in Germany and Poland. The company's plant propagation business, Bevo, contributed $23.9 million in revenue, showing 4% growth YoY.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has announced its upcoming annual general and special meeting scheduled for August 8, 2025, at 1:00 p.m. Eastern Time. The meeting will be held virtually via live webcast.
The company reminds shareholders to cast their votes before the proxy voting deadline of August 6, 2025, at 1:00 p.m. Eastern Time. The Board of Directors recommends voting in favor of all director nominees and proposed resolutions. Shareholders can access meeting materials on Aurora's website and SEDAR+, with voting available online or by telephone through Laurel Hill Advisory Group.